{"id":30,"date":"2020-08-20T13:22:42","date_gmt":"2020-08-20T04:22:42","guid":{"rendered":"https:\/\/www.nano-hd.com\/en\/?page_id=30"},"modified":"2025-12-18T13:33:45","modified_gmt":"2025-12-18T04:33:45","slug":"history","status":"publish","type":"page","link":"https:\/\/www.nano-hd.com\/en\/company\/history\/","title":{"rendered":"History"},"content":{"rendered":"
\n\n\n\n\n\n
2025<\/th>\n<\/tr>\n
Dec.<\/th>\nNano Holdings, Inc. changes its trade name
\nEnters the financial services sector
\nEstablishes subsidiary Nano Bridge Investment Co., Ltd.
\nAtsushi Matsumura appointed Chairman and President<\/td>\n<\/tr>\n
Mar.<\/th>\nSubsidiary PrimRNA Ltd establishes subsidiary PrimRNA AU in Australia.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2024<\/th>\n<\/tr>\n
Dec.<\/th>\nEstablishment of a subsidiary, NANO Rejuvenation Co., Ltd., dedicated exclusively to the aesthetic medicine business<\/td>\n<\/tr>\n
Aug.<\/th>\nJoint research agreement with Senju Pharmaceutical Co., Ltd. for the discovery of mRNA drugs<\/td>\n<\/tr>\n
Feb.<\/th>\nTUG1 ASO Started investigator-initiated trial for rGBM<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
2023<\/th>\n<\/tr>\n
Nov.<\/th>\nMoved head office in Minato-ku, Tokyo<\/td>\n<\/tr>\n
Jun.<\/th>\nCommenced sales of Comlex, an antibacterial otic solution
Changed company name to NANO MRNA Co., Ltd.<\/td>\n<\/tr>\n
Mar.<\/th>\nCOMLEX (development code: ENT103), an antibacterial otic solution received manufacturing and marketing approval.<\/td>\n<\/tr>\n
Jan.<\/th>\nConverted to a business model specializing in mRNA drug discovery.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2022<\/th>\n<\/tr>\n
Dec.<\/th>\nShiro Akinaga becomes President & CEO<\/td>\n<\/tr>\n
Apl.<\/th>\nShifted market listing from the “Mothers” section of the Tokyo Stock Exchange to the \u201cGrowth\u201d section.
Co-developer Ceolia Pharma Co., Ltd. filed an application for manufacturing and marketing approval of ENT103 for the treatment of otitis media and otitis externa.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2021<\/th>\n<\/tr>\n
Sep.<\/th>\nAccomplishment of Primary Endpoint in Phase III Clinical Study of ENT103\uff08otitis media\uff09<\/td>\n<\/tr>\n
Jun.<\/th>\nFast Track designationof NC-6300 (Epirubicin Micelle) by the U.S. FDA
Started Clinical trial of VB-111 in Japan as part of a joint, global phase III trial involving platinum-resistant ovarian cancer patients (OVAL study)
Moved head office in Chuo-ku, Tokyo
Moved Lab in kawasaki, Kanagawa
VB-111 Phase III clinical trial for platinum-resistant ovarian cancer started in Japan<\/td>\n<\/tr>\n
Apl.<\/th>\nEstablished AXCELEAD Inc. and PrimRNA Inc.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
2020<\/th>\n<\/tr>\n
Sep.<\/th>\nMerged with AccuRna, Inc.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2019<\/th>\n<\/tr>\n
Nov.<\/th>\nMr.Tetsuhito Matsuyama was inaugurated as President and CEO<\/td>\n<\/tr>\n
Jul.<\/th>\nStarted Phase II Clinical Study in Combination with Keytruda\u00ae for Squamous Cell Carcinoma of Head and Neck<\/td>\n<\/tr>\n
May<\/th>\nJoint research agreement with iCONM on therapeutic effect in combination with immune checkpoint inhibitor
\nStarted Phase III Clinical Study on ENT103 for Patients with Otitis media in Japan with Ceolia Pharma Co., Ltd.\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
2018<\/th>\n<\/tr>\n
Oct.<\/th>\nCommercial launch of renewal cosmetic essence “eclafutur d” (Collaboration with ALBION Co., Ltd.)<\/td>\n<\/tr>\n
Jul.<\/th>\nLicense and Collaborative Agreement with Orient Europharma for Global Study on new approach of using NC-6004 to treat Head and Neck Cancer<\/td>\n<\/tr>\n
Jun.<\/th>\nJoint Development Agreement with Ceolia Pharma Co., Ltd.<\/td>\n<\/tr>\n
Apl.<\/th>\nCapital and Business Alliance between NANO MRNA Co., Ltd., Noritsu Koki Co., Ltd. and Gene Techno Science Co., Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n
2017<\/th>\n<\/tr>\n
Nov.<\/th>\nEXCLUSIVE AGREEMENT FOR VB-111 IN JAPAN with VBL THERAPEUTICS<\/td>\n<\/tr>\n
Sep.<\/th>\nDepth Brand Started handling at Isetan Shinjuku
Release of scalp total care product “Depth For Share” for unisex<\/td>\n<\/tr>\n
Aug<\/th>\nEstablishment of US Subsidiary of NANO MRNA
Depth brand “Styling series” released<\/td>\n<\/tr>\n
Jul.<\/th>\nOrphan Drug Designationof NC-6300 (Epirubicin Micelle) by the U.S. FDA
Orphan Drug Designationof NC-6004 (biliary tract cancer) by the U.S. FDA<\/td>\n<\/tr>\n
Jun.<\/th>\nStarted Phase I\/II Clinical Study on NC-6300 for Patients with Rare Cancers in the U.S.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
2016<\/th>\n<\/tr>\n
Jun.<\/th>\nStarted Clinical Study in the EU in Relation to the Expansion of the Area for the Development of NC-6004<\/td>\n<\/tr>\n
May<\/th>\nLicensing Agreement with AccuRna Inc. and Investment in AccuRna Inc.<\/td>\n<\/tr>\n
Apl.<\/th>\nLaunch Albion “EXCIA AL IMMACULATE IDD” jointly developed product<\/td>\n<\/tr>\n
Mar.<\/th>\nLaunch scalp total care product “Depth” for men<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n
2015<\/th>\n<\/tr>\n
Dec.<\/th>\nStarted phase II clinical trial of NC-6004 (basket trial) in USA.<\/td>\n<\/tr>\n
Nov.<\/th>\nStarted phaseI clinical study (Head & Neck cancer)of NC-6004 in Japan.<\/td>\n<\/tr>\n
Sep.<\/th>\nNC-6004 to Participate in the Multinational Phase III Clinical Trial in Asia for Indication of Pancreatic Cancer<\/td>\n<\/tr>\n
Jul.<\/th>\nEstablished iCONM Labo. in kawasaki, Kanagawa.<\/td>\n<\/tr>\n
Mar.<\/th>\nEstablished Tokyo office in Chuo-ku, Tokyo.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2014<\/th>\n<\/tr>\n
Jun.<\/th>\nMoved head office,lab and Tokyo office to new facility near \u201cKashiwanoha Campus\u201d station in Kashiwa, Chiba.<\/td>\n<\/tr>\n
May<\/th>\nStarted phase Ib\/II clinical trial of NC-6004 (non small cell lung cancer) in USA.<\/td>\n<\/tr>\n
Feb.<\/th>\nOrient Europharma started Phase III clinical study (pancreatic cancer) of NC-6004 in Asia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n
2013<\/th>\n<\/tr>\n
Dec.<\/th>\nStarted phase I clinical trial of NC-4016 in USA.<\/td>\n<\/tr>\n
Oct.<\/th>\nCommercial launch of new cosmetic essence “eclafutur”(Collaboration with ALBION Co., Ltd.)<\/td>\n<\/tr>\n
Sep.<\/th>\nKOWA company Ltd. started Phase I clinical study of NC-6300 (K-912) in Japan<\/td>\n<\/tr>\n
Jun.<\/th>\nCollaborative research agreement for polymer with Shin-Etsu Chemical Co., Ltd.
Orient Europharma submitted IND\u3000for Phase III clinical study (pancreatic\u3000cancer) of Nanoplatin\u00ae (NC-6004) in Asia
IND submission for Phase Ib\/IIclinical study (non small cell lungcancer) of Nanoplatin\u00ae, (NC-6004) in USA
\n<\/tr>\n
May<\/th>\nIND submission for Phase I clinical\u3000study of DACH-platinum micelle(NC-4016) in USA
Kowa submitted IND for Phase I\u3000clinical study of NC-6300 (K-912) in Japan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
2012<\/th>\n<\/tr>\n
Nov.<\/th>\nNC-6004 New Licensing Agreement Between NANO MRNA and Orient Europharma.<\/td>\n<\/tr>\n
Oct.<\/th>\nStarted phase \uff29 clinical trial of Nanoplatin (NC-6004) in Japan.
Equity investment by Shin-Etsu Chemical Co., Ltd. into NANO MRNA by private placement.<\/td>\n<\/tr>\n
Jul.<\/th>\nCollaboration Agreement On Development of New Cosmetic Compounds with ALBION Co., Ltd.
Nippon Kayaku Co., Ltd. started phase III clinical trail(Breast Cancer) of Paclitaxel Micelle (NK105).<\/td>\n<\/tr>\n
Mar.<\/th>\nCollaborative research agreement with Eisai Co., Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2011<\/th>\n<\/tr>\n
Sep.<\/th>\nWorldwide license and co-development Agreement of Epirubicin Micelle (NC-6300) with KOWA company Ltd.<\/td>\n<\/tr>\n
Jul.<\/th>\nStarted phase \u2161 clinical trial of Nanoplatin (NC-6004) in Taiwan&Singapore.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2010<\/th>\n<\/tr>\n
Dec.<\/th>\nCollaborative research agreement with National Cancer Center to initiate a preclinical study of Epirubicin Micelle(NC-6300).<\/td>\n<\/tr>\n
Oct.<\/th>\nOption agreement of protein micelle for rhFVIIa with LFB Biotechnologies.<\/td>\n<\/tr>\n
Aug.<\/th>\nNippon Kayaku Co., Ltd. started phase I clinical trail(Breast Cancer) of Paclitaxel Micelle (NK105).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2009<\/th>\n<\/tr>\n
May<\/th>\nIn-licensed “Cationic Polyamino Acids” from the University of Tokyo and TOUDAI TLO, Ltd.<\/td>\n<\/tr>\n
Mar.<\/th>\nStarted phase I clinical trial of DACH-platin Micelle (NC-4016) in EU.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
2008<\/th>\n<\/tr>\n
Dec.<\/th>\nIND Application of Nanoplatin\u00ae for Phase I\/II study was approved in Taiwan<\/td>\n<\/tr>\n
Sep.<\/th>\nLicense and co-development Agreement of Nanoplatin (NC-6004) with Orient Europharma Co., Ltd.<\/td>\n<\/tr>\n
Apr.<\/th>\nExclusive License Agreement signed with Toudai TLO, Ltd. on Incorporated Nucleic Acids into Micelles<\/td>\n<\/tr>\n
Mar.<\/th>\nNANO MRNA got listed on the Tokyo Stock Exchanges Mothers<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2007<\/th>\n<\/tr>\n
Nov.<\/th>\nNippon Kayaku Co., Ltd. started phase II clinical trail(gastric cancer) of Paclitaxel Micelle (NK105).<\/td>\n<\/tr>\n
Feb.<\/th>\nIn-licensed \u201cA new block copolymer for preparation of pH-sensitive polymeric micelle and a production process thereof\u201d from the University of Tokyo and TOUDAI TLO, Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
2006<\/th>\n<\/tr>\n
Aug.<\/th>\nIn-licensed \u201cPhysical trapping type polymeric micelle drug preparation\u201d, for the research and development of paclitaxel micelle (NK105) with Japan Science and Technology Agency.<\/td>\n<\/tr>\n
Jul.<\/th>\nObtained exclusive license of \u201cElectrostatic bonding type macromolecular micelle drug carrier and drug carried thereon\u201d from TOUDAI TLO, Ltd.<\/td>\n<\/tr>\n
May<\/th>\nStarted phase I clinical trial of Nanoplatin\u00ae (NC-6004) in U.K.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2005<\/th>\n<\/tr>\n
Jul.<\/th>\nFormed partnership with TOUDAI TLO, Ltd for \u201cdiscovery and development of drugs with high usability for treatment of solid cancers\u201d.<\/td>\n<\/tr>\n
Mar.<\/th>\nFormed partnership with Debiopharm S.A. for DACH-Platin micelle (NC-4016).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
2004<\/th>\n<\/tr>\n
Aug.<\/th>\nMoved head office and lab to Tohdai Kashiwa Venture Plaza in Kashiwa, Chiba.<\/td>\n<\/tr>\n
May<\/th>\nNippon Kayaku Co., Ltd., a licensed company in Japan, started phase I clinical trial of Paclitaxel Micelle (NK105).
In-licensed \u201cCoordinate complex of diaminocyclohexaneplatinum (II) with block copolymer containing poly (carboxylic acid) segment and antitumor agent comprising the same\u201d from the University of Tokyo and TOUDAI TLO, Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
2003<\/th>\n<\/tr>\n
Jul.<\/th>\nEstablished Tokyo office in Chuo, Tokyo.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
2002<\/th>\n<\/tr>\n
Jun.<\/th>\nOut-licensed Paclitaxel Micelle to Nippon Kayaku Co., Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
2001<\/th>\n<\/tr>\n
Jan.<\/th>\nIn-licensed \u201cPolymeric micelle containing cisplatin enclosed therein and use thereof\u201d from the Center for Advanced Science and Technology Incubation Ltd. (now TOUDAI TLO, Ltd.).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
1999<\/th>\n<\/tr>\n
Oct.<\/th>\nMoved head office to Tokatsu Techno Plaza in Kashiwa, Chiba, and established the lab.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
1997<\/th>\n<\/tr>\n
Aug.<\/th>\nFormed partnership with Nippon Oil & Fats Co., Ltd. (now NOF Corporation) on joint development and supply of a new block copolymer (after then, entered into a supply agreement on exclusive manufacture and supply of polymer on December 2003).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n
1996<\/th>\n<\/tr>\n
Jun.<\/th>\nFounded in Setagaya, Tokyo, with the purpose of applying new block copolymers to develop pharmaceuticals and put them into practice.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

2025 Dec. Nano Holdings, Inc. changes its trade name Enters the financial services sector Establishes subsidia […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3911,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/pages\/30"}],"collection":[{"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/comments?post=30"}],"version-history":[{"count":13,"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/pages\/30\/revisions"}],"predecessor-version":[{"id":4705,"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/pages\/30\/revisions\/4705"}],"up":[{"embeddable":true,"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/pages\/3911"}],"wp:attachment":[{"href":"https:\/\/www.nano-hd.com\/en\/wp-json\/wp\/v2\/media?parent=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}